12 February 2021 - - The US government has purchased an additional 100m doses of US-based biotechnology company Moderna, Inc's (NASDAQ: MRNA) COVID-19 Vaccine, bringing its confirmed order commitment to 300m doses, the company said.

Moderna has supplied 41m released doses of the vaccine to the US government to date.

More than 22 m Americans have received the Moderna COVID-19 Vaccine in the US, according to the US Centers for Disease Control and Prevention.

Moderna remains on track to deliver the first 100m doses in 1Q21 and the second order of 100m doses in the second quarter of 2021.

Moderna is working with its domestic manufacturing partners and the US FDA to continue to explore ways to accelerate delivery, with the goal of providing this new order of 100m doses before the end of July 2021.

Moderna will continue to leverage the company's US-based manufacturing infrastructure to supply the Moderna COVID-19 Vaccine to the US government.

The Moderna COVID-19 Vaccine is an mRNA vaccine against COVID-19 encoding for a prefusion stabilized form of the Spike (S) protein, which was co-developed by Moderna and investigators from the National Institute of Allergy and Infectious Disease's (NIAID) Vaccine Research Center.